Our Health Care division has become Croda Pharma

Croda Pharma has seen exceptional growth across its high purity excipients and vaccine adjuvants, and in 2021 celebrated the acquisition of Avanti Polar Lipids, bringing in a strong pipeline of novel lipids and formulation capabilities in-house.

The company continues to expand its breadth of solutions, enabling 250 new programmes in 2021, targeting a range of therapeutic areas including oncology, malaria, HIV, and diabetes. 

Recently, the company celebrated winning the prestigious “Best Supplier for COVID-19 Vaccine Development” at BVOIA Vaccine awards, 2022. The awards give recognition to exceptional biologics and vaccine experts, and technologies that facilitate R&D and biologics manufacturing excellence. 

The award came just days after the new strategy of Croda Pharma, ‘Empowering biologics delivery’, was launched at the World Vaccines Congress in Washington DC where Croda Pharma presented its work supporting vaccines globally.  
Freek Snieders, Senior Vice President – Croda Pharma, said: “This is exactly what Croda is all about – Smart science to improve lives™. Our great achievements and focus on innovation and deep formulation expertise has continued to propel us forwards as a leading partner for biopharma. Becoming ‘Croda Pharma’ is a natural progression and represents the joining of three powerful business areas. It represents a single partner that will empower biologics drug delivery for years to come. That is Croda Pharma.”

Croda Pharma continues to expand its offering in innovative speciality excipients, vaccine adjuvant systems, and lipids, in order to support the biopharma industry with unparalleled quality and expertise.